Sponsored Links

Featured Links

Other Topics
Sponsored Links







Quote of the Day

"A good hockey player plays where the puck is. A great hockey player plays where the puck is going to be."

Wayne Gretzky






Click here for eBay Motors!


 






 
Featured Drugs Articles

Beware of Acne Cyst! Take the Precautions Necessary:
People are exposed in many elements outside and inside their homes. In a world today wherein pollution is abundant, many things arises specially the skin problems. The unhealthy habits usually cause problems in skin. Skin is the largest organ in the ...

Quit Smoking
Consider this: Already since 1972, over 60 million people in the USA alone have successfully quit smoking! At one stage over 60% of the adult population was addicted to this drug. Today it is 28% and dropping. Now, isn't this a fair thought. If all ...

The Pharmaceutical Drug Cartel and the FDA
According to the Los Angeles Times, the California Association of Physicians and Surgeons, and even the Center for Diseases Control’s own admission, well over 100,000 people in this country die each year from “properly” administered prescription drugs. ...




Arthritis Drugs Celebrex-Vioxx Safety in Doubt
 
“Arthritis drugs Vioxx, Celebrex safety in doubt”

In doubt and may not be as safe as previously thought. Research earlier this
year has shown that these drugs increased the risk of heart attacks although a
relatively low risk, over those taking a pain reliever. The FDA is debating
whether to add information about the increased risk on both drugs’ labels.
One Wall Street analyst has warned that this problem could have an adverse
effect on Merck, the drug company responsible for these drugs be placed on the
market - along with Pharmacia, which makes Celebrex, generating $2.3 billion in
12 months to March 31 of this year, Merck having sold $1.7 billion Vioxx during
the same 12 months.

Studies done last year showed that patients taking Vioxx had four times the risk
of heart attacks over patients taking Naproxen - another pain reliever. Naproxen
is also sold under the brands names of Naprosyn and Aleve. The risk of heart
attacks increases over time, at about four heart attacks per 1,000 patients.
This study was sponsored by the Merck company, which also stated that their
research does not show this problem of increased heart attacks with Vioxx.

These two drugs are among the best-sellers of prescription drugs in the world.
They cause fewer ulcers that many other drugs given for pain. Richard R. Stover,
a pharmaceutical industry analyst at Arnhold & S. Bleichroeder Inc, reported on
April 27 that he did his own analysis on what he called “disturbing data” from
Merck’s study. He stated that he was warning his clients, many of whom were
institutional investors holding stock in Merck, that they should watch the issue
carefully because it could effect the company’s stock price.

Dr. M. Michael Wolfe, chief of the gastroenterology section at the Boston
University School of Medicine and a member of the FDA advisory committee stated
that there should be a warning, after a review of the issue earlier this year,
stating that
“The marketing of these drugs is unbelievable, I’m sure there are many people
out there who are taking these drugs that should not be.”

There is a current debate going on between some doctors and Merck’s scientists
as to whether the higher risk of heart attacks is a result of Vioxx causing
damage in some patients or to an absence of the benefits that Naproxen may have
in protecting the heart, that Naproxen stops or slows the production of
thromboxane, which is thought to cause platelet in the blood to form clots,
similar to the aspirin effect.

Vioxx and Celebrex have been shown to have the same benefit in protecting the
heart.

Several doctors say they are worried about the possibility of heart attacks
because many of the arthritis patients


taking the drugs are elderly and have a
higher risk of cardiovascular problems to begin with.
The current debate centers on whether the higher heart attack rate found in
patients taking Vioxx is a result of the drug’s actually causing damage in some
patients or to an absence of the heart-protecting benefits that Naproxen may
have.

“Naproxen had a similar anti-platelet effect to aspirin,” said Dr. Eve E.
Slater, senior vice president of external policy for Merck’s research labs,
“and those people had fewer heart attacks.”

Neither Vioxx nor Celebrex has been shown to have the same heart-protecting
benefit.

Slater also said that Stover’s report was flawed and biased in favor of
Pharmacia. But regulators and some doctors say they still worry that there may
be more of a problem with Vioxx.

And even if Vioxx and Celebrex do not damage the heart, the fact that they do
not have the heart-protecting benefits of aspirin reduces the ability of the
companies to market them as being significantly safer than other pain relievers.

Merck recommended last year that doctors involved in clinical trials of Vioxx
consider prescribing low doses of aspirin to patients taking Vioxx if they are
at high risk of heart attacks - although low doses of aspirin could increase the
risk of ulcers. Ulcers are the main side effect that Vioxx and Celebrex were
developed to avoid.

There have been no studies done to determine whether patients have fewer ulcers
if they take low doses of aspirin with either Vioxx or Celebrex. In February
Dr Maria Lourdes Villalba, at an FDA advisory meeting, stated that Merck had
proved Vioxx [Rofecoxib] caused fewer serious ulcers than Naproxen. However,
she also state that the potential safety advantage was offset by a higher risk
of heart problems,in her opinion. She reported that “Overall, there was no
safety superiority of Rofecoxib over Naproxen, mainly due to an excess of serious
cardiovascular events”.

Dr Villalba also stated that there had been no studies to prove Merck’s claim that
Naproxen worked like aspirin in decreasing heart attacks. The FDA expressed some
concern over the higher rate of heart attacks with Vioxx, stating that this could
be caused by the drug’s ability to produce blood clots.

“There is still a tremendous benefit with these drugs” reported Dr Eve Slater of
Merck.



About the Author
Margot B, Writer, Web Developer
Margot B has written a book and hundreds of articles, specializing in health and the environment.

mailto:margotb@wonderport.com
Web Sites by Margot B:
http://margot.bravepages.com
http://margotsnews.gossimer.net
http://websitebuilder4free.Biz-Page.com
http://www.freewebz.com/nuchatlaht




Google


Drugs News


eMaxHealth.com

Flu Found Resistant to Main Antiviral Drug
New York Times, United States - 2 hours ago
By DONALD G. McNEIL Jr. Virtually all the flu in the United States this season is resistant to the leading antiviral drug Tamiflu, and scientists and health ...
Excessive use of antiviral drugs could aid deadly flu, says study Hindu
Excess use makes bird flu drug futile Times of India
Drugs' effect on bird flu doubted Denver Post
Colorado Daily - Science Daily (press release)
all 44 news articles

ABC News

Positive step for drug from engineered goat
USA Today - 20 hours ago
A Food and Drug Administration evaluation released Wednesday found that the drug Atryn is effective and safe. The report will be presented Friday to FDA's ...
US FDA staff backs CSL, GTC blood clot drugs Reuters
Goat modified for drug making sparks fears United Press International
FDA Supports Drug Made From Genetically Engineered Goats dBTechno
eFluxMedia - Xconomy
all 382 news articles

dBTechno

FDA Scientists Ask Obama to Restructure Drug Agency
Wall Street Journal - 5 hours ago
By ALICIA MUNDY and JARED A. FAVOLE WASHINGTON -- A group of scientists at the US Food and Drug Administration on Wednesday sent a letter to President-elect ...
US expanding list of illegal weight-loss drugs Dallas Morning News
The Value Of New Drugs Is Dropping Forbes
Adverse drug reactions in pets DVM 360
USA Today - Times of the Internet
all 54 news articles

Wall Street Journal Blogs

Behind the Health Spending Data
New York Times, United States - 16 hours ago
The chief reason for the overall slowdown was much slower growth in spending on prescription drugs. Retail spending on prescription drugs rose only 4.9 ...
Spending on prescription drugs slows USA Today
Feds modify Medicare drug plan YourWestValley.com
Costs of health care slow Greenville News
Wall Street Journal Blogs - New York Times
all 554 news articles

Javno.hr

More US funds freed for Mexico's drug fight
Los Angeles Times, CA - 13 hours ago
Washington releases an additional $99 million as part of an aid package to help security forces in their battle with drug cartels. ...
Mexico drug war likely to intensify Seattle Times
US releases $99 million of Mexico anti-drug money The Associated Press
US Releases Millions More To Aid In Mexico's Drug War KFOXtv.com
Newspaper Tree - El Paso Times
all 110 news articles